| Literature DB >> 29160029 |
Jing Xu1, Mengxiao Yu1, Chuanqi Peng1, Phoebe Carter1, Jia Tian2, Xuhui Ning1, Qinhan Zhou1, Qiu Tu3, Greg Zhang1, Anthony Dao1, Xingya Jiang1, Payal Kapur4,5, Jer-Tsong Hsieh5, Xudong Zhao3, Pengyu Liu2, Jie Zheng1,5.
Abstract
While dose dependencies in pharmacokinetics and clearance are often observed in clinically used small molecules, very few studies have been dedicated to the understandings of potential dose-dependent in vivo transport of nanomedicines. Here we report that the pharmacokinetics and clearance of renal clearable gold nanoparticles (GS-AuNPs) are strongly dose-dependent once injection doses are above 15 mg kg-1 : high dose expedited the renal excretion and shortened the blood retention. As a result, the no-observed-adverse-effect-level (NOAEL) of GS-AuNPs was >1000 mg kg-1 in CD-1 mice. The efficient renal clearance and high compatibility can be translated to the non-human primates: no adverse effects were observed within 90 days after intravenous injection of 250 mg kg-1 GS-AuNPs. These fundamental understandings of dose effect on the in vivo transport of ultrasmall AuNPs open up a pathway to maximize their biomedical potentials and minimize their toxicity in the future clinical translation.Entities:
Keywords: biocompatibility; dose dependencies; nanoparticles; non-human primates; renal clearance
Mesh:
Substances:
Year: 2017 PMID: 29160029 PMCID: PMC5909189 DOI: 10.1002/anie.201710584
Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN: 1433-7851 Impact factor: 15.336